ZDA
IONS icon

Zweig-DiMenna Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Zweig-DiMenna Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,200
Closed -$242K – 250
2015
Q2 		$242K Buy
+4,200
New +$267K 0.01% 214
2014
Q2 		– Sell
-5,100
Closed -$220K – 275
2014
Q1 		$220K Buy
+5,100
New +$247K 0.01% 220

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Zweig-DiMenna Associates's IONS Position: Q3 2015 in Review

Zweig-DiMenna Associates sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 4,200 shares — an estimated $242K sold.

Zweig-DiMenna Associates first reported a position in IONS in Q1 2014 and held it in 2 quarters. The position peaked at $242K in Q2 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

  • Zweig-DiMenna Associates reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 4,200 Ionis Pharmaceuticals shares in Q3 2015, an estimated $242K.
  • Zweig-DiMenna Associates first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Zweig-DiMenna Associates's Ionis Pharmaceuticals position peaked at $242K in Q2 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2015, filed 9 Nov 2015.